Vitiligo — The Science, the Treatments, the Honest Evidence.

1. What vitiligo actually is.

The color of your skin, your hair, and the inside of your eyes comes from a single pigment called melanin. Melanin is made by specialized cells called melanocytes, which sit at the junction between the outer layer of skin (epidermis) and the layer just beneath it (dermis). Each melanocyte hands off its pigment to roughly 30–40 surrounding skin cells, like a single artist supplying paint to a whole neighborhood.

Vitiligo is what happens when those melanocytes are destroyed in localized patches. Where they used to be, the skin still works — it sweats, it senses touch, it heals — but it has no pigment. The result is a white or off-white patch on otherwise normal skin. The patches are usually well-defined, often symmetric on both sides of the body, and most commonly appear on the face, hands, around body openings (eyes, mouth, genitals), and at sites of friction or pressure^[1].

Two things follow from the "no melanocytes" picture:

• Hair in the patches can turn white too. Hair color comes from the same cells. When a patch contains white hairs (called leukotrichia), it usually means the melanocyte reservoir in the hair follicle has also been destroyed — and that patch is harder to repigment.
• Depigmented skin burns very easily. Melanin is your skin's natural sunscreen. Without it, sunburn happens in a fraction of the usual exposure, and the long-term skin-cancer math shifts. Sun protection on lesional skin isn't cosmetic — it's medical.

2. Who gets it, when, and where on the body.

Vitiligo affects roughly 0.5–2% of people worldwide — somewhere between 1 in 200 and 1 in 50 — across every ethnicity and skin tone^[1,2]. The Krüger & Schallreuter 2012 worldwide-prevalence review pulled together population data from 50+ studies and found the rate remarkably stable across countries; the disease is not more common in any one part of the world^[2].

It can start at any age, but about half of cases appear before the age of 20, and roughly a quarter before age 10^[1]. Men and women are affected at roughly equal rates — but women are over-represented in clinics because the social pressure to treat is heavier.

The patches favor specific places: the face (especially around the eyes and mouth), the hands and wrists, the elbows and knees, the armpits and groin, and the genitals. These are also the areas with the heaviest cosmetic and psychological impact, which is why two patients with the same total surface area of disease can have very different lived experiences.

Family history matters. Roughly 15–20% of patients have a first-degree relative with vitiligo, and a much larger fraction have a family history of other autoimmune disease (thyroid disease, type 1 diabetes, alopecia areata, pernicious anemia, rheumatoid arthritis, lupus). The Spritz & Santorico 2021 review summarizes the genetic architecture — over 50 risk loci identified, most of them in immune-regulation genes, supporting the autoimmune mechanism we'll unpack in §3^[3].

3. Why it happens — an autoimmune attack on melanocytes.

For decades, vitiligo was considered a mystery condition. The last twenty years have nailed down the core mechanism: in vitiligo, the immune system mistakes your own melanocytes for a threat and kills them. The killer cells are a specific kind of T cell (CD8⁺ cytotoxic T cells) trained to recognize melanocyte-specific proteins. Underneath this is a second contributor — oxidative stress inside the melanocyte itself, which seems to be the original trigger that makes the cell "look wrong" to the immune system in the first place^[1,6].

The single most important mechanistic insight of the last 15 years was nailed down in 2014. Mehdi Rashighi and John Harris at UMass showed that the entire immune attack runs through a chemical signal called CXCL10 (and its sister CXCL9), released by the melanocyte itself under stress and read by the immune system through a receptor called CXCR3. Blocking CXCL10 in their mouse model stopped depigmentation from progressing and even partially reversed it^[4]. The earlier Harris 2012 paper had already shown that the whole process required IFN-γ (a master immune-signaling protein) — kill IFN-γ and the killer T cells can't accumulate in the skin^[5].

That insight is what unlocked the JAK-inhibitor era. JAK proteins are the relay station for IFN-γ inside cells — block JAK, and the IFN-γ → CXCL10 → killer-cell loop quiets down. Both the topical drug ruxolitinib (Opzelura, FDA-approved 2022, §8a) and the oral drug ritlecitinib (phase 2b trial 2023, §8c) work on this pathway. They are not coincidences — they are the direct translation of Rashighi and Harris's mouse work into human medicine.

The oxidative-stress contributor. Karin Schallreuter's group has spent decades documenting that vitiligo melanocytes — and the skin around them — show abnormally high levels of hydrogen peroxide (H₂O₂) and reactive nitrogen species, which damage the cellular machinery that makes melanin. Reducing H₂O₂ with topical pseudocatalase produced partial repigmentation in their early trials^[6]. The current synthesis is that oxidative stress damages the melanocyte first, releases stress signals that flag it to the immune system, and the immune system finishes the job.

Genetics set the susceptibility. The Spritz lab's GWAS work has identified over 50 risk loci, most of them in immune-regulation genes that are shared with other autoimmune diseases (thyroid disease, type 1 diabetes, lupus, rheumatoid arthritis)^[3]. This is why the conditions cluster in families, and why vitiligo is increasingly understood as one expression of a broader autoimmune predisposition.

4. Subtypes — segmental, non-segmental, focal, universalis.

Getting the subtype right matters enormously, because the subtypes behave differently, respond to different treatments, and carry different prognoses. The current international classification was set at the 2011 Vitiligo Global Issues Consensus Conference, formalized in the Ezzedine 2012 paper that every modern dermatologist references^[7].

One word the Ezzedine consensus deliberately retired: "vitiligo vulgaris". The new umbrella term is just vitiligo, with the subtype as a modifier. The consensus also formally recognised the Koebner phenomenon (new lesions at sites of trauma, §5) as a hallmark feature, with a defined grading system used in clinical trials^[7].

5. Triggers — Koebner, sunburn, chemical phenols, stress.

Vitiligo doesn't appear randomly. Many patients can point to a specific event — a sunburn, a deep cut, a course of emotional stress — that preceded the first patch or a flare. Four triggers are well documented^[1].

The Koebner phenomenon. New vitiligo patches that appear at sites of physical injury — surgical scars, cuts, burns, friction from belts and watch straps, sunburn. This isn't a coincidence: the injured skin releases stress signals that recruit the same CXCR3⁺ killer T cells from §3 to the wound site. Koebner-positive disease is a feature in the Ezzedine 2012 classification and is treated as a sign of an actively unstable immune attack^[7].

Sunburn. A bad sunburn at the right (wrong) moment in a susceptible person can trigger the first patches or a flare. The mechanism is the same as Koebner — UV damages the skin, releases inflammatory signals, brings the killer cells.

Chemical phenols and catechols. A specific group of industrial chemicals — monobenzyl ether of hydroquinone, paratertiary butyl phenol, para-amino phenol — are directly toxic to melanocytes and can trigger occupational vitiligo in workers exposed to them (rubber and adhesive industries especially). These same chemicals are used deliberately in §8e (monobenzone) to depigment the remaining skin in universalis cases^[12]. Hair dyes and leather/rubber goods are the most common consumer-product exposures.

Stress. The connection between major life stressors and vitiligo onset/flares is well documented in cohort studies and is consistent with the broader pattern that stress increases inflammatory tone and oxidative stress^[1]. It's not the cause — the genetic and immune predisposition has to be present — but it's a real precipitant in susceptible people.

6. The conditions that travel with vitiligo.

Vitiligo is part of a cluster — if you have one autoimmune condition, your odds of having another are higher than the general population's. The 2025 Liu et al meta-analysis of USA-based studies pulled together the cleanest set of comorbidity prevalence estimates to date^[8]. The biggest single association — by a wide margin — is with autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease). The order-of-magnitude picture:

The practical implication: if you've been diagnosed with vitiligo, ask your primary-care doctor for a baseline workup — at minimum TSH and free T4 (thyroid), fasting glucose + HbA1c (diabetes screen), B12 and ferritin (anemia screen), and consider anti-TPO antibodies if any thyroid symptoms exist. This is not over-testing; it's the standard of care given the comorbidity background rates^[1,8].

7. How dermatologists diagnose it.

Vitiligo is mostly a clinical diagnosis — a trained eye recognizes the pattern, the borders, and the body-site distribution. A few specific tools sharpen the picture:

Wood's lamp. A handheld ultraviolet light (~365 nm). Under Wood's light in a dark room, depigmented vitiligo patches glow bright bluish-white because there's no melanin to absorb the UV. This is especially useful on lighter skin tones, where vitiligo can be hard to see in normal light, and for spotting early or "confetti" lesions before they're obvious to the naked eye^[1].

Vitiligo Area Scoring Index (VASI). A simple body-region-based scoring system that estimates total depigmented body surface area. It's the standard tool used in clinical trials (Opzelura, ritlecitinib) and is what your dermatologist tracks at follow-up visits to see whether you're getting better, stable, or worse^[1].

Dermoscopy. A handheld magnifier (and sometimes camera) the derm uses to look at lesion edges. Active vitiligo shows characteristic features — perifollicular pigment loss, micro-Koebner patterns, "confetti" depigmentation — that distinguish it from look-alikes (pityriasis alba, post-inflammatory hypopigmentation, halo nevi, tinea versicolor).

Biopsy. Rarely needed for typical cases. Reserved for atypical presentations where the diagnosis is unclear or another condition is on the differential. The histology is straightforward — a complete absence of melanocytes at the dermal-epidermal junction in the patch, with normal-looking melanocytes at the edge.

8a. Topical treatments — including the first FDA-approved repigmenting drug.

Topical (creams, ointments) treatment is usually the first line. Three options dominate.

High-potency corticosteroids.

Once-daily clobetasol or betamethasone, applied for 2–3 months at a time. Most affordable, decades of use. The catch: long-term steroid use on facial or skinfold skin causes thinning (atrophy), telangiectasias (visible small blood vessels), and stretch marks. Generally used as a short course to stop active spread, not a long-term plan^[1].

Topical calcineurin inhibitors — tacrolimus 0.1% / pimecrolimus 1%.

Steroid-sparing immunosuppressants safe for long-term use on the face and skinfolds (areas where steroids cause the worst side effects). Twice-daily application, often combined with NB-UVB phototherapy for the face. Effective on facial and neck patches, less so on hands and feet^[1].

Ruxolitinib cream 1.5% (Opzelura) — the first FDA-approved repigmenting drug.

Approved by the FDA in July 2022 for non-segmental vitiligo in patients aged 12 and older — the first drug ever approved with the specific indication of "repigmenting vitiligo," not just calming inflammation. Mechanism: blocks the JAK1/JAK2 enzymes inside skin cells, which interrupts the IFN-γ → CXCL10 → killer-cell loop from §3.

The pivotal evidence: two identical phase 3 trials (TRuE-V1 and TRuE-V2) randomized 674 patients with non-segmental vitiligo to twice-daily Opzelura or vehicle (placebo) for 24 weeks, with an open-label extension to 52 weeks^[9]. The pre-specified primary endpoint was the proportion of patients achieving ≥75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) at week 24.

The honest read: about half of patients on the face will hit a substantial repigmentation milestone at 1 year — a real improvement over the historical baseline, but not a guarantee, and treatment needs to be sustained. The drug works fastest on the face, slowest on hands and feet, and basically not at all on white-haired lesions where the follicular melanocyte reservoir is gone^[9].

Safety. The most common side effect is application-site acne or itching. Because oral JAK inhibitors (the systemic relatives, §8c) carry a boxed warning for serious infections, blood clots, and cancer, the cream carries the same boxed warning by class — even though systemic exposure from a topical is very low. The labeled cap is 10% body surface area at any one time^[9].

8b. Phototherapy — narrow-band UVB and the 308 nm excimer laser.

Narrow-band ultraviolet B (NB-UVB) phototherapy at 311 nm is the workhorse for moderate-to-extensive vitiligo and has been the de facto standard treatment for the last two decades^[1]. Mechanistically it does two things at once: it dampens the local immune attack on melanocytes, and it stimulates surviving melanocytes (especially the reservoir at the hair-follicle base) to repopulate the patch.

Typical protocol. Whole-body cabinet sessions 2–3 times per week, each lasting under a minute initially and titrated up over weeks. Treatment continues for a minimum of 3–6 months before judging response, and often 12+ months for a full course. The face and neck respond best; hands and feet are most resistant. NB-UVB pairs very well with topical tacrolimus or ruxolitinib for maximum repigmentation.

308 nm excimer laser. A focused, higher-intensity UVB source that targets individual patches rather than the whole body. Useful when only a few small areas need treatment. Faster results per session but more expensive per session.

Home NB-UVB units. Wall-mounted or handheld units with prescription-grade NB-UVB bulbs are available for home use. They're significantly cheaper over a year than in-clinic phototherapy and avoid the logistics of 2–3 visits per week. They require careful protocol-following (treatment times, eye protection, body-rotation), and should be prescribed and supervised by a dermatologist familiar with phototherapy — not bought blind off the internet.

8c. Oral JAK inhibitors — ritlecitinib and the next wave.

For active, widespread non-segmental vitiligo where topical and phototherapy aren't enough, oral JAK inhibitors are the leading edge of the field. They target the same IFN-γ/CXCL10 pathway as Opzelura (§8a), but systemically — every melanocyte in your body sees the drug.

The cleanest evidence is the Ezzedine et al 2023 phase 2b trial of ritlecitinib (a JAK3/TEC kinase inhibitor already FDA-approved for severe alopecia areata) in 364 adults with active non-segmental vitiligo^[10]. After 24 weeks of treatment, the highest-dose arm achieved a mean ~22% improvement in facial VASI from baseline, with continued improvement out to 48 weeks. The drug also stabilized disease — significantly fewer patients on ritlecitinib developed new patches during the trial vs placebo. Phase 3 trials are ongoing.

Other oral JAK inhibitors (upadacitinib, povorcitinib, baricitinib) have all shown activity in vitiligo in earlier-phase trials and are advancing in development. The field is moving fast — what's true about systemic options in 2024 will likely look outdated by 2027.

The trade-off. Oral JAK inhibitors as a class carry boxed warnings for serious infections, major cardiovascular events, blood clots, and cancer — based on long-term safety data in older patient populations with rheumatoid arthritis. Whether those signals translate to a younger, healthier vitiligo population is genuinely debated. For now, oral therapy is reserved for active, progressive, widespread disease where the cosmetic and psychological burden justifies the risk profile — and the decision belongs with a derm and patient together, not a self-driver from this page.

8d. Surgical grafting — for stable segmental disease.

For patients whose disease has been completely stable for at least 12 months — typically segmental vitiligo that has run its course and stopped spreading — surgical melanocyte transplant is a curative option for the affected patches. The principle: harvest melanocytes from a healthy donor area on the same patient (no immune-rejection issue), and place them into the depigmented patch where they take root and repigment the area.

The dominant modern technique is melanocyte-keratinocyte transplantation procedure (MKTP), also called non-cultured cellular grafting. A small piece of normally pigmented skin is shaved from a donor site (typically the buttock or thigh), enzymatically broken down into a suspension of melanocytes and keratinocytes, and painted onto the recipient site that has been gently dermabraded to receive the cells. A pressure dressing is left in place for a week.

The Silpa-Archa et al 2017 long-term follow-up in the Journal of the American Academy of Dermatology tracked 60 MKTP procedures across 32 patients out to a median of ~25 months. Stable segmental vitiligo showed the best outcomes — most patients achieved >75% repigmentation in the treated areas. Non-segmental vitiligo responded less reliably, particularly if the disease was active or unstable^[11].

Who is and isn't a candidate. Required: stable disease for ≥12 months, no new patches, no Koebner phenomenon (the procedure itself is a controlled trauma — if you Koebnerize, you'll get vitiligo at the donor site). Best candidates are children and young adults with localized segmental disease. MKTP is offered at academic dermatology centers with vitiligo programs; it is not a generic dermatology-office procedure.

8e. Depigmentation — going the other way for vitiligo universalis.

For patients with very extensive vitiligo (vitiligo universalis, >80% body surface area depigmented), the equation can flip. Chasing further repigmentation of the small remaining pigmented islands is impractical; instead, the remaining pigmented skin is deliberately depigmented to match the rest of the body. The result is uniformly white skin and a coherent appearance.

The standard agent is monobenzyl ether of hydroquinone (monobenzone), 20% cream, applied 1–2 times daily to the remaining pigmented skin. It is directly toxic to melanocytes — destroying them locally and, through immune cross-reactivity, often beyond the application site. Full depigmentation takes 1–3 years of consistent use. The AlGhamdi & Kumar 2011 review in the Journal of the European Academy of Dermatology and Venereology summarized the clinical experience and outlines patient-selection criteria^[12].

This is an irreversible decision. Once depigmented, the skin will not regain pigment. Lifelong strict sun protection becomes mandatory because depigmented skin has no UV defense. Psychological and counseling preparation is part of the decision pathway — most centers require this before initiating treatment.

9. Diet, supplements, and lifestyle — honest evidence grading.

More online content exists about diet and supplements for vitiligo than about every other treatment combined — and the evidence base supports almost none of it. The honest summary:

Vitamin D. Vitiligo patients are more likely to be vitamin D deficient than matched controls in observational studies — but causality runs in both directions (depigmented skin is told to avoid the sun, which lowers D production). Correcting an actual deficiency is sensible general medicine. There is no compelling evidence that high-dose vitamin D supplementation in a non-deficient vitiligo patient drives repigmentation^[1].

Vitamin B12 and folate. Worth checking, especially given the pernicious-anemia association from §6. Correct deficiencies if found. The "B12 + folate as a cure for vitiligo" claim from older small case series has not held up in controlled trials.

Antioxidants (ginkgo, polypodium leucotomos, alpha-lipoic acid, vitamin E). The mechanistic logic — countering the oxidative stress in §3 — is appealing, and a handful of small trials have shown modest signals (especially ginkgo and polypodium as adjuncts to phototherapy, not as standalone therapy). The evidence is far below what's needed to recommend any of these as primary treatment.

Specific food eliminations. Anti-gluten, anti-dairy, anti-nightshade, "low-sugar," "low-inflammatory" diets — none are supported by replicated clinical-trial evidence for vitiligo. If you have coexisting celiac disease (which is mildly more common in vitiligo cohorts, per ^[8]), treating the celiac is its own indication; eliminating gluten in a celiac-negative vitiligo patient is unsupported.

Sun protection on lesional skin. The one lifestyle move with unambiguous evidence value. Depigmented skin has no melanin, burns rapidly, and accumulates UV damage. Broad-spectrum SPF 30+ on patches, sun-protective clothing, and shade-seeking during peak hours are medical, not cosmetic.

10. Mental health, stigma, and camouflage.

The medical literature has consistently underplayed how heavy the psychological burden of vitiligo is. The Picardo 2015 primer is unusual in giving quality-of-life impact the space it deserves — depression, anxiety, social avoidance, and reduced sexual function are all documented at rates well above the general population, and the impact does not scale linearly with body surface area^[1]. A small patch on the face can carry more psychological weight than extensive disease hidden under clothes.

Camouflage products (Dermablend, Vitiligo Inc, Microskin, Cover FX) are professionally formulated waterproof skin-color matched cosmetics designed for vitiligo and other pigment differences. They are not a substitute for medical treatment, but they are not "vanity" either — they are a quality-of-life intervention that lets people get on with daily life while slower medical treatments take effect. Medical tattoo (micropigmentation) is a more permanent option used in some cases for specific small areas (lip vermilion, areolae, eyebrows).

Psychological support. Cognitive-behavioral therapy and patient-support communities are part of comprehensive vitiligo care at academic centers. The Vitiligo Research Foundation, Global Vitiligo Foundation, and national patient-organization websites maintain support-group directories. If the visible disease is meaningfully impacting your daily life, ask your dermatologist for a referral to a psychologist who works with skin patients — it is part of the standard-of-care offering, not an add-on.

11. Where do you stand? An interactive self-assessment.

Fifteen items mapped to the disease features and treatment levers above. Tick what's true for you. Instead of a single 0–15 score, the panel shows a profile across four lanes — disease subtype, current activity, autoimmune comorbidity risk, and treatment-readiness — and surfaces the conditional questions worth bringing to a dermatologist visit. Nothing is sent anywhere; the score is saved only to your own browser so you can revisit and update it as your situation changes.